Skip to content
MarketScale
‹ Back to IndustriesHealthcare

M&A Healthcare Advisors (MAHA) Exclusively Represents On My Care Home Health in their Sale to Excelin Health

M&A Healthcare Advisors (MAHA), a newly founded boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of On My Care Home Health, a large Home Health agency providing skilled nursing, physical, occupational, and speech therapy, as well as social worker and home aide services. Located in the San Francisco Bay area,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
M&A Healthcare Advisors (MAHA) Exclusively Represents On My Care Home Health in their Sale to Excelin Health

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

M&A Healthcare Advisors (MAHA), a newly founded boutique merger and acquisition (M&A) advisory group, is proud to announce the sale of On My Care Home Health, a large Home Health agency providing skilled nursing, physical, occupational, and speech therapy, as well as social worker and home aide services. Located in the San Francisco Bay area, On My Care was acquired by Excelin Health, a portfolio company of Corinthian Equity Fund II, L.P.

“We are excited to add On My Care to our larger portfolio and continue their tradition of excellence. Andre Ulloa and his team at M&A Healthcare Advisors went above and beyond to shepherd this transaction through closing and were integral to getting the deal done. Andre was the consummate intermediary: attentive, responsive, and consistent throughout the entire process.” – Maureen Spivack, President of MAS Advisory Services, LLC and Board Member of Excelin Health.

While the current M&A market has shown signs of slowing down in recent months, with the right support and guidance, transactions are still occurring. The M&A Healthcare Advisors team was able to create increased value for On My Care, successfully navigate through every phase of the sale process, and identify a buyer with unique synergies who would continue building upon their legacy.

“We regularly speak about how our involvement directly increases the probability of a company being sold and drives the enterprise value of the businesses we represent. The sale process for On My Care Home Health is a direct testament to those principles, our experience, and Andre’s remarkable daily effort to ensure the best outcome for our client”, say Co-Founders Mike Moran & Mark Thomas

This success proves the effectiveness of M&A Healthcare Advisors’ approach only 8 months after their founding.

“The team at M&A Healthcare Advisors [MAHA] was the perfect complement for us as a seller. They matched my work ethic and quick responsiveness. They were supportive, taking on all sale’s process tasks which did not require my involvement, allowing me to focus on my operations.

Although the tangible work product was excellent, what was most impressive to me was their technical consistency and emotional fortitude through a very arduous due diligence process. There were many evenings we would spend on the phone assessing that day’s events and adjusting our approach for the days to come. MAHA introduced me to our transactional attorneys, as well; all the while working side-by-side with the legal team to ensure that every aspect of the purchase agreement was as good as it could be.

In the end, after an eight-month process, all parties walked away with a mutually beneficial deal. I thank that, in large part, to the efforts of MAHA.” – Hans Gill, CEO of On My Care Home Health

About M&A Healthcare Advisors

M&A Healthcare Advisors (MAHA), is a boutique merger and acquisition (M&A) advisory group, focused on the lower-middle market healthcare industry. Our core purpose is to provide comprehensive, efficient, and committed transactional support for emerging or established, lower-middle market healthcare businesses. Our team is highly accessible, experienced, process-driven, and seeks to bring a superior level of guidance to every engagement. We relentlessly advocate for our clients, constantly reinforcing the most essential value: TRUST.

With over 50 successful healthcare transactions in the past five years, the team at M&A Healthcare Advisors has sold companies in a variety of healthcare segments: Behavioral Health, Autism, I/DD, Hospice, Home Health, Home Care, Private Duty, Physical Therapy, Staffing/Medical Recruiting, Not-for-Profits and all types of Pharmacy. Their full suite of services includes Sell-Side Representation, M&A Hourly Consulting, and Expert Valuation services.

Business Contact

Mark Thomas

Partner, Director of Operations

M&A Healthcare Advisors

mthomas@mahealthcareadvisors.com

Media Contact

Matt Santoro

matt@elkordyglobal.com

SOURCE M&A Healthcare Advisors

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512